Literature DB >> 24554218

Combination of calcium hydroxyapatite and autologous blood for endoscopic treatment of vesicoureteral reflux in children.

Roozbeh Tanhaeivash1, Abdol-Mohammad Kajbafzadeh, Atefeh Zeinoddini, Neda Khalili, Mona Vahidi Rad, Reza Heidari.   

Abstract

OBJECTIVE: To report the results of endoscopic correction of vesicoureteral reflux (VUR) with concomitant injection of pure calcium hydroxyapatite (CaHA) and autologous blood. PATIENTS AND METHODS: Records of patients who underwent endoscopic correction of VUR using concomitant injection of CaHA and autologous blood from 2008 through 2010 were retrospectively reviewed. Data regarding patients' demographics, preoperative VUR grades, febrile urinary tract infections, complications of procedure, postoperative VUR grades and cure rates were collected. Voiding cystourethrography was performed 3 months postoperatively.
RESULTS: Total number of 23 children (9 girls and 14 boys) with 40 refluxing ureters were included. The mean age of children was 1.9 ± 0.97 (SD) years. Reflux grades were II to IV in 14, 11 and 15 renal refluxing units (RRUs), respectively. The mean follow-up period was 44 months. VUR was successfully treated in 87.5% of RRUs after three injections. Significant statistical difference was found between VUR grades before and after the first, second and third injections (p < 0.001, p = 0.001 and p = 0.011, respectively). Moreover, there was a significant difference between primary reflux grade and treatment success (p = 0.031). Febrile UTI was resolved in 85% of patients (17 of 20 patients with febrile UTI) after endoscopic treatment which shows significant improvement (p < 0.001). The procedure was uneventful in all patients, and no obstruction was reported during the follow-up period.
CONCLUSION: Concomitant injection of pure CaHA without any additives (hyaluronic acid, etc.) and autologous blood can be an effective, repeatable and cost-benefit approach for the management of children suffering VUR with a success rate of 87.5% after three injections.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24554218     DOI: 10.1007/s11255-014-0659-4

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  35 in total

1.  Endoscopic subureteral injection treatment with calcium hydroxylapatite in primary vesicoureteral reflux.

Authors:  Bilal Eryildirim; Fatih Tarhan; Uğur Kuyumcuoğlu; Erkan Erbay; Gökhan Faydaci
Journal:  Int Urol Nephrol       Date:  2007       Impact factor: 2.370

Review 2.  Long-term results of endoscopic treatment of vesicoureteric reflux with different tissue-augmenting substances.

Authors:  Boris Chertin; Stanislav Kocherov
Journal:  J Pediatr Urol       Date:  2009-11-05       Impact factor: 1.830

3.  Correction of vesicoureteral reflux in children by endoscopic collagen injection: a prospective study.

Authors:  M Reunanen
Journal:  J Urol       Date:  1995-12       Impact factor: 7.450

4.  Preliminary evaluation of calcium hydroxylapatite as a transurethral bulking agent for stress urinary incontinence.

Authors:  R Mayer; M Lightfoot; I Jung
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

5.  Preliminary data on endoscopic treatment of vesicoureteric reflux with polyacrylate polyalcohol copolymer (Vantris®): surgical outcome following single injection.

Authors:  Boris Chertin; Wael Abu Arafeh; Alexander Zeldin; Stanislav Kocherov
Journal:  J Pediatr Urol       Date:  2010-12-30       Impact factor: 1.830

6.  [Endoscopic treatment of the vesicoureteral reflux in children: preliminary experience with the subureteral injection of Coaptite].

Authors:  Miguel Julián Mora Durbán; Francisco Javier Navarro Sebastián; María Belén Muñoz Delgado; Jesús Isidoro García González; Pedro Dionisio Paniagua Andrés
Journal:  Arch Esp Urol       Date:  2006-06       Impact factor: 0.436

7.  Single injection results of endoscopic treatment of vesicoureteric reflux with different tissue-bulking substances in patients with end stage renal failure.

Authors:  Ayhan Dirim; Eray Hasirci; Tahsin Turunc; Cem Aygun; Hakan Ozkardes
Journal:  J Endourol       Date:  2011-04-10       Impact factor: 2.942

8.  Endoscopic Subureteral Injection for the Treatment of Vesicoureteral Reflux in Children: Polydimethylsiloxane (Macroplastique(R)) versus Dextranomer/Hyaluronic Acid Copolymer (Deflux(R)).

Authors:  Young Dae Bae; Min Gu Park; Mi Mi Oh; Du Geon Moon
Journal:  Korean J Urol       Date:  2010-02-18

9.  Treatment of vesico-ureteric reflux: a new algorithm based on parental preference.

Authors:  N Capozza; A Lais; E Matarazzo; S Nappo; M Patricolo; P Caione
Journal:  BJU Int       Date:  2003-08       Impact factor: 5.588

10.  Outcome of endoscopic treatment for vesicoureteral reflux in children using polydimethylsiloxane.

Authors:  Adel A Al-Hunayan; Elijah O Kehinde; Mamdouh A Elsalam; Rola S Al-Mukhtar
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

View more
  1 in total

1.  Pelvic floor electromyography and urine flow patterns in children with vesicoureteral reflux and lower urinary tract symptoms.

Authors:  Lida Sharifi-Rad; Seyedeh-Sanam Ladi-Seyedian; Hossein Amirzargar; Abdol-Mohammad Kajbafzadeh
Journal:  Int Braz J Urol       Date:  2018 Nov-Dec       Impact factor: 1.541

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.